OTE Staff Reports

Researchers assessed accommodative changes after foldable iris-fixated phakic IOL implantation for myopic astigmatism

A scoping review finds limited evidence on transition programmes for adolescents moving from paediatric to adult ophthalmology care

The CE-marked lens is being placed by selected surgeons across 6 European countries under a company-described early-access program

After accounting for key factors like eye length, researchers found no meaningful differences in corneal biomechanics between primary open-angle and primary angle-closure glaucoma.

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module

The 17th European Glaucoma Society (EGS) Congress—being held in Brussels, Belgium, from 30 May to 2 June 2026—brings together glaucoma specialists across plenary sessions, hands-on surgical dry labs, national society symposia and cross-specialty debates.

The novel dual-port cutter, designed for use with the Stellaris Elite platform, offers increased flow rate and reduced cutter vibration.

The dual-function phaco-vitrectomy platform is cleared for European commercialization, with launch targeted for Q3 2026.

The 17th annual Congress on Controversies in Ophthalmology takes place on 20–21 March 2026 in Kraków, Poland, bringing together an international faculty for two days of structured debate on the most pressing questions in the field.

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.

Experts share practical and research-based advancements, offering actionable strategies in diagnosis, treatment, and early detection.

The certification supports continued European market access as the Medical Device Regulation imposes stricter requirements on manufacturers.

The group recommends using “physicians” for doctors and “clinicians” or “health care professionals” for care teams.

Mild cases of retinopathy of prematurity may improve without treatment, but some cases require treatment to keep ROP from causing significant visual impairment and even blindness.

The technology uses excimer laser energy to create microscopic openings in the trabecular meshwork to re-establish the natural flow of aqueous.

The technology is used to treat glaucoma at the same time as cataract surgery.

Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.

At Angiogenesis, Dr David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

During her talk at Angiogenesis, Dr Anat Loewenstein outlines how artificial intelligence could revolutionize diabetic retinopathy screening.

At Angiogenesis, Dr SriniVas R. Sadda discusses how choriocapillaris may predict the rate of progression of atrophy.

According to Haag-Streit UK, the iScan80 is a high-speed OCT system ideal for practices seeking an affordable and versatile OCT system.

Dr Ted Leng discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.

Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.

Researchers at the University of Virginia School of Medicine have made a discovery linking lupus, a potentially debilitating autoimmune disorder, and macular degeneration, a leading cause of blindness.

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

The agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries.

At the 2021 American Academy of Ophthalmology annual meeting, Dr Penny Asbell discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.

Dr Jay Duker discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.